| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Cara Therapeutics, Inc. | 2,631,067 | 4.8% | EDGAR |
| SC 13G/A | 2024-02-13 | Bain Capital Life Sciences Opportunities III, LP | Cara Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-01-29 | BlackRock Inc. | Cara Therapeutics, Inc. | 3,554,258 | 6.5% | EDGAR |
| SC 13G/A | 2023-07-25 | Vifor (International) Ltd | Cara Therapeutics, Inc. | 7,396,770 | 13.7% | EDGAR |
| SC 13G/A | 2023-07-07 | BlackRock Inc. | Cara Therapeutics, Inc. | 3,701,968 | 6.9% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Cara Therapeutics, Inc. | 3,101,724 | 5.8% | EDGAR |
| SC 13G/A | 2023-01-26 | BlackRock Inc. | Cara Therapeutics, Inc. | 7,730,529 | 14.4% | EDGAR |
| SC 13G/A | 2023-01-20 | BlackRock Inc. | Cara Therapeutics, Inc. | 7,730,529 | 14.4% | EDGAR |
| SC 13G | 2022-11-18 | Bain Capital Life Sciences Opportunities III, LP | Cara Therapeutics, Inc. | 2,696,030 | 5.0% | EDGAR |
| SC 13G/A | 2022-02-15 | FIRST MANHATTAN CO | Cara Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | RHO Ventures VI LP | Cara Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2022-02-09 | VANGUARD GROUP INC | Cara Therapeutics, Inc. | 3,032,762 | 5.7% | EDGAR |
| SC 13G/A | 2022-01-28 | BlackRock Inc. | Cara Therapeutics, Inc. | 7,199,126 | 13.5% | EDGAR |
| SC 13G/A | 2021-10-21 | Vifor (International) Ltd | Cara Therapeutics, Inc. | 7,396,770 | 13.9% | EDGAR |
| SC 13G/A | 2021-05-07 | BlackRock Inc. | Cara Therapeutics, Inc. | 7,234,277 | 14.5% | EDGAR |
| SC 13G/A | 2021-02-16 | PRICE T ROWE ASSOCIATES INC /MD/ | Cara Therapeutics, Inc. | 2,429,235 | 4.8% | EDGAR |
| SC 13G | 2021-02-16 | FIRST MANHATTAN CO | Cara Therapeutics, Inc. | 3,212,796 | 6.4% | EDGAR |
| SC 13G/A | 2021-02-12 | RHO Ventures VI LP | Cara Therapeutics, Inc. | 2,799,058 | 5.6% | EDGAR |
| SC 13G/A | 2021-01-29 | BlackRock Inc. | Cara Therapeutics, Inc. | 3,632,266 | 7.3% | EDGAR |
| SC 13G | 2020-10-23 | Vifor (International) Ltd | Cara Therapeutics, Inc. | 4,114,379 | 8.3% | EDGAR |